Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors

被引：149

作者：

Holzer, Philipp ^{[1
]}

Masuya, Keiichi ^{[1
]}

Furet, Pascal ^{[1
]}

Kallen, Joerg ^{[1
]}

Valat-Stachyra, Therese ^{[1
]}

Ferretti, Stephane ^{[1
]}

Berghausen, Joerg ^{[1
]}

Bouisset-Leonard, Michele ^{[1
]}

Buschmann, Nicole ^{[1
]}

Pissot-Soldermann, Carole ^{[1
]}

Rynn, Caroline ^{[1
]}

Ruetz, Stephan ^{[1
]}

Stutz, Stefan ^{[1
]}

Chene, Patrick ^{[1
]}

Jeay, Sebastien ^{[1
]}

Gessier, Francois ^{[1
]}

机构：

[1] Novartis Inst BioMed Res, CH-4002 Basel, Switzerland

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2015年 / 58卷 / 16期

关键词：

P53-MDM2; INTERACTION; ANTAGONISTS; PATHWAY;

D O I：

10.1021/acs.jmedchem.5b00810

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

As a result of our efforts to discover novel p53:MDM2 protein-protein interaction inhibitors useful for treating cancer, the potent and selective MDM2 inhibitor NVP-CGM097 (1) with an excellent in vivo profile was selected as a clinical candidate and is currently in phase 1 clinical development. This article provides an overview of the discovery of this new clinical p53:MDM2 inhibitor. The following aspects are addressed: mechanism of action, scientific rationale, binding mode, medicinal chemistry, pharmacokinetic and pharmacodynamic properties, and in vivo pharmacology/toxicology in preclinical species.

引用

页码：6348 / 6358

页数：11

共 23 条

[1] Discovery of NVP-CGM097, a highly potent and optimized small molecule inhibitor of Mdm2 under evaluation in a Phase I clinical trial
Jeay, Sebastien
Berghausen, Joerg
Buschmann, Nicole
Chene, Patrick
Cozens, Robert
Erdmann, Dirk
Ferretti, Stephane
Furet, Pascal
Gabriel, Tobias
Gessier, Francois
Graus-Porta, Diana
Hofmann, Francesco
Holzer, Philipp
Ito, Moriko
Jacoby, Edgar
Jensen, Michael
Kallen, Joerg
Lang, Marc
Lisztwan, Joanna
Murakami, Masato
Pissot-Soldermann, Carole
Ruetz, Stephan
Rynn, Caroline
Sterker, Dario
Stutz, Stefan
Valat, Therese
Wiesmann, Marion
Masuya, Keiichi
[J]. CANCER RESEARCH, 2014, 74 (19)
[2] Mechanistic study of NVP-CGM097: a potent, selective and species specific inhibitor of p53-Mdm2
Valat, Therese
Masuya, Keiichi
Baysang, Frederic
Albrecht, Genevieve
Buschmann, Nicole
Erdmann, Dirk
Furet, Pascal
Gabriel, Tobias
Gessier, Francois
Hofmann, Francesco
Holzer, Philipp
Kallen, Joerg
Pissot-Solderman, Carole
Stutz, Stefan
Chene, Patrick
Jeay, Sebastien
[J]. CANCER RESEARCH, 2014, 74 (19)
[3] NVP-CGM097: a novel p53-Mdm2 inhibitor exhibiting potent antitumor activity in mouse models of human cancer
Ferretti, Stephane
Berger, Marjorie
Rebmann, Ramona
Santacroce, Francesca
Sterker, Dario
Jensen, Michael
Masuya, Keiichi
Jeay, Sebastien
[J]. CANCER RESEARCH, 2014, 74 (19)
[4] A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097
Jeay, Sebastien
Gaulis, Swann
Ferretti, Stephane
Bitter, Hans
Ito, Moriko
Valat, Therese
Murakami, Masato
Ruetz, Stephan
Guthy, Daniel A.
Rynn, Caroline
Jensen, Michael R.
Wiesmann, Marion
Kallen, Joerg
Furet, Pascal
Gessier, Francois
Holzer, Philipp
Masuya, Keiichi
Wurthner, Jens
Halilovic, Ensar
Hofmann, Francesco
Sellers, William R.
Porta, Diana Graus
[J]. ELIFE, 2015, 4
[5] The MDM2 Inhibitor NVP-CGM097 Is Highly Active in a Randomized Preclinical Trial of B-Cell Acute Lymphoblastic Leukemia Patient Derived Xenografts
Townsend, Elizabeth C.
DeSouza, Tiffany
Murakami, Mark A.
Montero, Joan
Stevenson, Kristen
Christie, Amanda L.
Christodolou, Alexandra N.
Vojinovic, Una
Kopp, Nadja
Barzagbi-Rinaudo, Patrizia
Murakami, Masato
Letai, Anthony
Jeay, Sebastien
Wuerthner, Jens
Halilovic, Ensar
Weinstock, David M.
[J]. BLOOD, 2015, 126 (23)
[6] NVP-HDM201: cellular and in vivo profile of a novel highly potent and selective PPI inhibitor of p53 Mdm2
Jeay, Sebastien
Chene, Patrick
Ferretti, Stephane
Furet, Pascal
Gruenenfelder, Bjoern
Guagnano, Vito
Guerreiro, Nelson
Halilovic, Ensar
Hofmann, Francesco
Kellen, Joerg
Leonard, Michelle
Mah, Robert
Masuya, Keiichi
Ramos, Rita
Rynn, Caroline
Ruetz, Stephan
Stachyra-Valat, Therese
Stutz, Stefan
Vaupel, Andrea
Wuerthner, Jens
Holzer, Philipp
[J]. CANCER RESEARCH, 2016, 76
[7] A phase I study of the MDM2 inhibitor AMG 232 in patients with advanced p53 wild type (p53WT) solid tumors or multiple myeloma
Langenberg, M. H.
Gluck, L.
Weger, V.
Frank, R.
Eskens, F.
Blay, J. Y.
Soria, J. C.
Chawla, S.
Gounder, M.
Wagner, A.
Zhang, Y.
Kambuj, P.
Loberg, R.
Henary, H.
[J]. EUROPEAN JOURNAL OF CANCER, 2016, 69 : S34 - S34
[8] A gene signature composed of 13 p53 target genes predicts for response to NVP-CGM097, a novel p53-Mdm2 inhibitor, in cell lines and in human primary tumor xenograft models
Jeay, Sebastien
Gaulis, Swann
Ferretti, Stephane
Albrecht, Genevieve
Barys, Louise
Guthy, Daniel
Halilovic, Ensar
Ito, Moriko
Murakami, Masato
Pornon, Astrid
Ruetz, Stephan
Venkatesan, Kavitha
Yu, Jianjun
Jensen, Michael
Wiesmann, Marion
Wuerthner, Jens
Graus-Porta, Diana
[J]. CANCER RESEARCH, 2014, 74 (19)
[9] Milademetan is a potent, murine double minute 2 (MDM2) inhibitor, highly active in TP53 wild-type (p53WT) Merkel cell carcinoma (MCC) cell lines
Ananthapadmanabhan, Varsha
Knott, Aine
Soroko, Kara M.
Gokhale, Prafulla C.
Tirunagaru, Vijaya
Doebele, Robert
DeCaprio, James A.
[J]. MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
[10] Discovery of RG7388, a Potent and Selective p53-MDM2 Inhibitor in Clinical Development
Ding, Qingjie
Zhang, Zhuming
Liu, Jin-Jun
Jiang, Nan
Zhang, Jing
Ross, Tina M.
Chu, Xin-Jie
Bartkovitz, David
Podlaski, Frank
Janson, Cheryl
Tovar, Christian
Filipovic, Zoran M.
Higgins, Brian
Glenn, Kelli
Packman, Kathryn
Vassilev, Lyubomir T.
Graves, Bradford
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (14) : 5979 - 5983

← 1 2 3 →